OBP2A and metabolic disease: To circumvent the limitations and known inflammatory side effects of adenoviral gene transduction and zoom-in on the hepatocyte-selective LCN13 functions, we thus aimed at the vigorous pre-clinical evaluation of LCN13’s therapeutic potential for metabolic disorders.